Literature DB >> 12034519

MLL amplification in myeloid malignancies: clinical, molecular, and cytogenetic findings.

Michelle Dolan1, Ronald C McGlennen, Betsy Hirsch.   

Abstract

Structural rearrangements involving the MLL gene at 11q23 are common recurring abnormalities in de novo and therapy-related hematologic disorders. MLL rearrangement most often results from translocation or partial tandem duplication, although recent published reports suggest a different mechanism by which MLL might participate in leukemogenesis: MLL amplification. We report two patients with myeloid disorders who showed amplification of MLL at diagnosis and who, like the majority of reported cases, had an older age at onset and on aggressive clinical course. Additionally, we summarize the salient clinical, cytogenetic and molecular findings of the 29 other cases of MLL amplification that have thus far been reported.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12034519     DOI: 10.1016/s0165-4608(01)00602-1

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Therapy-related pro-B cell acute lymphoblastic leukemia: report of two patients with MLL amplification.

Authors:  Frederick Racke; Carol Cole; Alison Walker; Jeffrey Jones; Nyla A Heerema
Journal:  Cancer Genet       Date:  2012-12-11

2.  Cytogenetic and Fluorescence in situ Hybridization Profile of Pediatric Acute Lymphoblastic Leukemia in a University Hospital in South India.

Authors:  Latha Sneha Magatha; Julius Xavier Scott; Gayathri Subramaniam; Thirugnanasambandan Chandrasekaran; Solomon Franklin Durairaj Paul; Teena Koshy
Journal:  Med Princ Pract       Date:  2021-07-07       Impact factor: 1.927

3.  Prenatal diagnosis of a de novo interstitial deletion of 11q (11q22.3 → q23.3) associated with abnormal ultrasound findings by array comparative genomic hybridization.

Authors:  Nian Liu; Jiong Yan; Xinlin Chen; Jieping Song; Bo Wang; Yanyi Yao
Journal:  Mol Cytogenet       Date:  2014-09-25       Impact factor: 2.009

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.